Progyny Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 8/78 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.10.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Progyny Inc's Score
Industry at a Glance
Industry Ranking
8 / 78
Overall Ranking
63 / 4582
Industry
Healthcare Providers & Services
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
29.100
Target Price
+17.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Progyny Inc Highlights
StrengthsRisks
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 48.33% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.17B.
Fairly Valued
The company’s latest PE is 40.80, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 88.02M shares, decreasing 24.51% quarter-over-quarter.
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Ticker SymbolPGNY
CompanyProgyny Inc
CEOAnevski (Peter)
Websitehttps://www.progyny.com/
FAQs
What is the current price of Progyny Inc (PGNY)?
The current price of Progyny Inc (PGNY) is 26.960.
What is the symbol of Progyny Inc?
The ticker symbol of Progyny Inc is PGNY.
What is the 52-week high of Progyny Inc?
The 52-week high of Progyny Inc is 27.510.
What is the 52-week low of Progyny Inc?
The 52-week low of Progyny Inc is 13.960.
What is the market capitalization of Progyny Inc?
The market capitalization of Progyny Inc is 2.32B.
What is the net income of Progyny Inc?
The net income of Progyny Inc is 54.34M.
Is Progyny Inc (PGNY) currently rated as Buy, Hold, or Sell?
According to analysts, Progyny Inc (PGNY) has an overall rating of Buy, with a price target of 29.100.
What is the Earnings Per Share (EPS TTM) of Progyny Inc (PGNY)?
The Earnings Per Share (EPS TTM) of Progyny Inc (PGNY) is 0.653.